This Article Full Text Full Text (PDF) All Versions of this Article: chest.07-1620v1 134/1/61    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Google Scholar Articles by Arzt, M. Articles by Pfeifer, M. PubMed PubMed Citation Articles by Arzt, M. Articles by Pfeifer, M. Related Content Related Editorial

Effects of Dynamic Bilevel Positive Airway Pressure Support on Central Sleep Apnea in Men With Heart Failure^*

^* From the Department of Internal Medicine II, Divisions of Pneumology and Cardiology (Drs. Arzt, Wensel, Schroll, and Riegger), University of Regensburg, Regensburg; the Center for Pneumology (Drs. Schichtl, Montalvan, Budweiser, and Pfeifer), Donaustauf Hospital, Donaustauf; and Prosper Hospital (Dr. Blumberg), Recklinghausen, Germany.

Correspondence to: Michael Arzt, MD, Department of Internal Medicine II, Pneumology, University of Regensburg, Franz-Josef-Strauβ-Allee 11, 93042 Regensburg, Germany; e-mail: michael.arzt{at}klinik.uni-regensburg.de

Abstract

Background: Treatment with continuous positive airway pressure (CPAP) improves cardiac function in chronic heart failure (CHF) patients with central sleep apnea (CSA)-Cheyne-Stokes respiration (CSR) by stabilizing ventilation, but frequently central apneas and hypopneas persist. Our objective was to test the hypothesis that flow-targeted dynamic bilevel positive airway pressure (BPAP) support (BiPAP autoSV; Respironics; Murrysville, PA) effectively suppresses CSR-CSA in CHF patients.

Methods: We studied 14 CHF patients with CSR-CSA (and residual CSA on positive airway pressure therapy) during 3 consecutive nights: (1) diagnostic polysomnography, (2) CPAP (n = 10) or BPAP (n = 4) titration, and (3) dynamic flow-targeted dynamic BPAP support with an expiratory positive airway pressure (EPAP) set to suppress obstructive respiratory events, and an inspiratory positive airway pressure (IPAP) dynamically ranging between 0 and 15 cm H₂O above the EPAP.

Results: CPAP or BPAP significantly reduced the apnea-hypopnea index (AHI) [mean ± SD, 46 ± 4 events/h to 22 ± 4 events/h; p = 0.001] compared to the first night without treatment. Flow-targeted dynamic BPAP support (mean EPAP, 6.5 ± 1.7 cm H₂O; maximal IPAP, 21.9 ± 2.1 cm H₂O) further reduced the AHI to 4 ± 1/h of sleep compared to the untreated (p < 0.001) and CPAP or BPAP night (p = 0.002). After the first night of flow-targeted dynamic BPAP support, patients rated on an analog scale (range, 0 to 10) the treatment as comfortable (6.9 ± 0.6), and the sleep quality as improved compared to previous nights (7.4 ± 0.6).

Conclusion: Flow-targeted dynamic BPAP support effectively suppresses CSR-CSA in patients with CHF and is well tolerated.

Key Words: cardiology • central sleep apnea • ventilation

Related Editorial

Filling in the Gaps: The Role of Noninvasive Adaptive Servoventilation for Heart Failure-Related Central Sleep Apnea

Lee K. Brown
Chest 2008 134: 4-7. [Full Text] [PDF]

This article has been cited by other articles:

				L. K. Brown Filling in the Gaps: The Role of Noninvasive Adaptive Servoventilation for Heart Failure-Related Central Sleep Apnea Chest, July 1, 2008; 134(1): 4 - 7. [Full Text] [PDF]